The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a beneficial treatment option for patients with acute myeloid leukemia (AML). Prior to transplantation, patients require myeloablative conditioning (MAC) and although intensive conditioning decreases the risk of relapse, it induces high toxicity. Reduced intensity conditioning (RIC) as an alternative to MAC, helps to reduce toxicity but increases the risk of transplant rejection. Oral mucositis as a result of cytostatic, impaired immune system function and decreased salivation, is one of the most common oral complications of high-dose chemotherapy observed in early hematopoietic stem cell transplantation (HSCT). Oral erosions and ulcers that develop because of oral mucositis, serve as a portal of entry for viral, fungal, and bacterial antigens, and these infections, consequently, increase morbidity and mortality post-HSCT. However, as the use of allo-HSCT increases gradually in older adults and patients with comorbidities, there is a need to understand the occurrence of oral mucositis in patients with AML after allo-HSCT.
Wysocka-Słowik et al,1 recently published a study in Annals of Hematology, investigating the frequency and severity of oral mucositis depending on the type of conditioning regimen in patients with AML post-allo-HSCT.
A prospective cohort study in patients diagnosed with AML who had undergone allo-HSCT. Eligible patients (N = 80) were allocated to either MAC (n = 54) or RIC (n = 26) regimen based on age and comorbidities. Cytostatics included in the MAC group were fludarabine, busulfan, melphalan, and treosulfan, individually adjusted to each patient’s profile and applied in appropriate proportions as FluBu4, and the RIC group included fludarabine, busulfan, cytarabine, and total body irradiation (TBI), used as FluBu2 or Flu-CyTBI.
Table 1. Five-point scale*
WHO, World Health Organization. |
|
Mucositis grade† |
WHO criteria |
---|---|
0 |
No signs |
1 |
Oral soreness +/− erythema, no erosions, oral discomfort |
2 |
Oral erythema, ulcers; solid diet tolerated |
3 |
Diffuse oral erythema, ulcers; liquid diet only |
4 |
Severe inflammation, diffuse inflammatory-necrotic lesions; alimentation not possible |
Patients in the MAC group comprised 30 women and 24 men, with a mean age of 42±12 years, and 12 women and 14 men with a mean age of 56±13 years in the RIC group.
At preliminary examination, 84% of all patients demonstrated Grade 0 mucositis. However, at the first posttransplant examination this decreased to 34% of patients demonstrating Grade 0 mucositis, and a further decrease to 26% after the second posttransplant examination (Table 2), representing a statistically significant difference between first and second examination (p < 0.0001).
Table 2. Incidence of oral mucositis*
WHO, World Health Organization. |
|||
Mucositis grade† |
All patients (N = 80) |
||
---|---|---|---|
Preliminary examination |
First examination |
Second examination |
|
0 |
84 |
34 |
26 |
1 |
13 |
43 |
33 |
2 |
4 |
15 |
28 |
3 |
0 |
6 |
10 |
4 |
0 |
2 |
4 |
Table 3. Incidence of oral mucositis based on type of conditioning*
examin., examination; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; WHO, World Health Organization. |
||||||
Mucositis grade† |
MAC (n = 54) |
RIC (n = 26) |
||||
---|---|---|---|---|---|---|
Preliminary examin. |
First examin. |
Second examin. |
Preliminary examin. |
First examin. |
Second examin. |
|
0 |
85 |
26 |
17 |
84 |
50 |
46 |
1 |
13 |
46 |
31 |
12 |
35 |
35 |
2 |
2 |
19 |
33 |
4 |
8 |
15 |
3 |
0 |
7 |
15 |
0 |
4 |
0 |
4 |
0 |
2 |
4 |
0 |
4 |
4 |
Figure 1. Incidence of oral mucositis*
MAC, myeloablative conditioning; RIC, reduced intensity conditioning; WHO, World Health Organization.
*Adapted from Wysocka-Słowik et al.1
†Five-point scale recommended by the WHO.
The study demonstrated that oral mucositis occurred less frequently and with lower intensity in patients with RIC therapy compared to MAC therapy. Quality of life due to oral mucositis is greatly reduced in patients with AML leading to premature termination of treatment. With the continuous growth of allo-HSCT as a treatment option for patients with AML, it warrants further investigation of oral mucositis in these patients.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content